Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA to require vision loss warning on GLP-1 drug labels

The labelling requirement stems from the findings of a 2024 study and subsequent FDA trials that tested the results of that study.

FDA to require vision loss warning on GLP-1 drug labels

We haven't written up this one. Global News has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at globalnews.ca →

More in Health & Medicine

More from Tuesday 10 November →